ecosystem / people / mingjie-xie
M

Mingjie Xie

Co-founder & CEO, Rapid Novor

BiotechKitchener

Mingjie Xie is co-founder and chief executive of Rapid Novor, the Kitchener-Waterloo biotech that sequences antibodies directly from protein rather than DNA. He started it in 2015 with University of Waterloo professor Bin Ma and Qixin Liu. The company raised a US$5 million Series A in 2020 and in 2021 reported sequencing polyclonal antibodies purely from protein.

Mingjie hasn’t spoken on a TechTO, TechVancouver or TechWaterloo stage. This profile is here because Mingjie co-founded Rapid Novor, which appears in 1 talk in the archive.

Around the web ×1

Quick answers

Did Mingjie Xie co-found Rapid Novor?

Yes. Rapid Novor's about page, checked September 23, 2026, lists "Mingjie Xie, Co-founder and CEO" alongside "Qixin Liu, Co-founder and CTO" and co-founder and chief scientist Dr. Bin Ma, and says the company was founded in 2015 by three people.

What is his role at Rapid Novor today?

Chief executive. The company's about page, checked September 23, 2026, gives his title as "Co-founder and CEO", and Rapid Novor's April 7, 2026 PRWeb release on its Princess Margaret Cancer Centre EasyM study names him as the company's media contact.

What has Rapid Novor done under him?

The University of Waterloo's David Johnston Research + Technology Park reported on July 31, 2020 that Rapid Novor had closed a "$5 million USD" Series A and quoted Xie, as "Founder and CEO", saying "there is currently no other technology available to directly sequence and profile antibody proteins from blood." Communitech's reprint of a May 27, 2021 company release quotes him calling it "the first time in the world that animal polyclonal antibodies have been de novo sequenced successfully purely from protein."

Is Rapid Novor still operating?

Yes. Rapid Novor announced on March 10, 2026 that its diagnostic laboratory had received a provisional licence from the Ontario Ministry of Health for its EasyM multiple myeloma blood test, and on April 7, 2026 that patient enrolment was complete in a Princess Margaret Cancer Centre study of EasyM.

Suggest an edit
This is you? Claim this profileAsk to be removed
Know someone who belongs here? Suggest a profile
Maintained by TechTO · facts sourced and dated · last reviewed Sep 23, 2026